Volitionrx shares jump 12.39% after-hours as company prepares reimbursement submission for Nu.Q Cancer assays in France with HCL support.

Volitionrx surged 12.39% in after-hours trading following the announcement of preparing a reimbursement submission for its Nu.Q® Cancer assays in France, supported by Hospices Civils de Lyon (HCL). The submission, expected by quarter-end under France’s RIHN framework, marks a critical step toward commercializing the test in routine clinical practice, with potential routine adoption by late 2026. HCL’s endorsement and the test’s demonstrated clinical utility in lung cancer management underscored the milestone, positioning Volitionrx to expand market access and licensing opportunities. The news aligns with the company’s strategic focus on epigenetics-driven diagnostics and reinforces investor confidence in its growth trajectory.